Back to School: How biopharma can reboot drug development. Access exclusive analysis here
In a double-blind, cross-over Phase I trial in 35 healthy volunteers, Indiplon IR was well tolerated and did not produce
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury